Virology Specimen Collection Market Report 2026

The virology specimen collection market size has grown strongly in recent years. It will grow from $6.96 billion in 2025 to $7.39 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to expansion of infectious disease testing programs, increased hospital diagnostic volumes, rising awareness of early viral detection, growth of centralized laboratory testing, standardization of clinical sampling protocols.

The virology specimen collection market size is expected to see strong growth in the next few years. It will grow to $9.22 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing demand for decentralized diagnostics, rising adoption of home-based sample collection, expansion of surveillance testing programs, growing investments in laboratory automation, increasing focus on rapid diagnostic turnaround. Major trends in the forecast period include increasing demand for standardized specimen collection kits, rising use of viral transport media, growing adoption of automated sample handling, expansion of point-of-care collection solutions, enhanced focus on sample integrity and stability.

The growing number of blood donations is fueling the growth of the virology specimen collection market. As the volume of blood samples increases, there is a corresponding rise in the testing and detection of viruses in blood through virology specimen collection methods. For instance, in June 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, approximately 118.54 million blood donations were collected globally. About 40% of these donations were collected in high-income countries, representing roughly 16% of the world’s population. Around 13,300 blood centers in 169 countries reported collecting a total of 106 million donations. Therefore, the demand for virology specimen collection is expected to rise in line with the increasing number of blood donations.

Major companies operating in the market are focusing on developing innovative solutions such as automated sample isolation and real-time amplification technologies to improve diagnostic accuracy and provide clinically relevant information for optimal antiviral therapies. Automated sample isolation and real-time amplification technologies enable faster and more precise identification of clinically significant viruses, allowing healthcare providers to tailor antiviral treatments and enhance patient outcomes. For instance, in August 2023, Nightingale Health Plc, a Finland-based health technology company, launched a remote blood collection kit for its medical research and clinical trial clients. Using the Nightingale Kit and its self-collection tool, participants can prick their own finger to collect a blood sample, greatly increasing flexibility and enabling studies that were previously limited by logistical or geographic constraints. Additionally, remote blood collection can be seamlessly and cost-effectively integrated into research since Nightingale Health provides both sample collection and analysis.

In April 2024, Eurofins Scientific, a Luxembourg-based testing laboratory company, acquired Ascend Clinical LLC for an undisclosed amount. This acquisition strategically enhances Eurofins’ diagnostic services, particularly for patients with kidney disease and those requiring transplant care. With the rising demand for specialized healthcare solutions, this expansion is particularly timely. Ascend Clinical is a US-based clinical testing services provider catering specifically to the needs of renal patients.

Major companies operating in the virology specimen collection market are Puritan Medical Products Co. LLC, Becton Dickinson and Company, Quidel Corporation, Trinity Biotech plc, DiaSorin S.p.A., Vircell S.L., Copan Italia S.p.A., Hardy Diagnostics, Laboratory Corporation of America Holdings, ZeptoMetrix Corporation, Copan Diagnostics Inc., Bionote Inc., F. Hoffmann-La Roche Ltd, Meridian Bioscience Inc., Hologic Inc., Cepheid Inc., Bio-Rad Laboratories Inc., GenMark Diagnostics Inc., Luminex Corporation, Abbott Laboratories, BioFire Diagnostics LLC, Randox Laboratories Ltd., Savyon Diagnostics Ltd., Seegene Inc., Serosep Ltd., SolGent Co. Ltd., TECOmedical AG, Vela Diagnostics, Zybio Inc.

North America was the largest region in the virology specimen collection market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virology specimen collection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the virology specimen collection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the virology specimen collection market by increasing costs of imported plastics, swabs, transport media components, and automated collection devices. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported consumables, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising procurement expenses and affecting supply availability during demand surges. At the same time, they are supporting local manufacturing of collection kits, regional supplier diversification, and domestic production of transport media.

The virology specimen collection market research report is one of a series of new reports that provides virology specimen collection market statistics, including virology specimen collection industry global market size, regional shares, competitors with a virology specimen collection market share, detailed virology specimen collection market segments, market trends and opportunities, and any further data you may need to thrive in the virology specimen collection industry. This virology specimen collection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A virology specimen is a blood or other biological sample collected to examine for the presence of infections. Virus isolation specimens should be collected within four days of the onset of illness, as virus shedding decreases significantly after that period. Virus cultures are generally not useful for specimens collected more than seven days after symptom onset, with some exceptions. These specimens are used by government health authorities, hospitals, clinicians, and laboratories for diagnostic purposes.

The main types of virology specimen collection include blood collection kits, specimen collection tubes, viral transport media, and swabs. Sample collection kits consist of vials and reagents used to collect samples and transport them to laboratories for testing. Virology specimens can include blood samples, nasopharyngeal samples, throat samples, nasal samples, cervical samples, oral samples, and other manually or automatically collected samples that are used for diagnostic and therapeutic purposes.

The virology specimen market consists of sales of conjunctiva (eye) swab, cerebral spinal fluid (csf), lesions, tissue specimens, and bone marrow. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.